Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: final data from a multicenter, investigator-blind, randomized study

Kircik, L.; Green, L.; Thiboutot, D.; Tanghetti, E.; Wilson, D.; Dhawan, S.; Parr, L.

Journal of Drugs in Dermatology Jdd 8(9): 812-818

2009


ISSN/ISBN: 1545-9616
PMID: 19746673
Document Number: 11633
A solubilized 5% BPO gel has been developed to enhance the bioavailability, follicular penetration, and efficacy of BPO. Sixty-five patients with moderate facial acne vulgaris were randomly assigned to apply solubilized 5% BPO gel to one facial side and 5% BPO/1% clindamycin to the contralateral side, twice daily for four or 12 weeks. The solubilized BPO gel resulted in significantly greater reductions in non-inflammatory lesion count than BPO/clindamycin at weeks 1, 2, 3, 4 and 12 and comparable reductions in inflammatory lesion count at all time points. Mean values for patient satisfaction with acne improvement were comparable and mean levels of erythema, dryness, peeling, stinging/burning and itching were consistently less than mild. Compared with BPO/clindamycin, the solubilized BPO gel offers significantly greater reductions in non-inflammatory lesion count and comparable reductions in inflammatory lesion count in the absence of an antibiotic.

Document emailed within 1 workday
Secure & encrypted payments

Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: final data from a multicenter, investigator-blind, randomized study